

REMARKS

It is respectfully asserted that the sequence disclosure contained in the application now fully complies with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825.

It is respectfully submitted that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.


Pursuant to 37 C.F.R. §1.821 (f), the undersigned hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.

Additionally, it is respectfully submitted that the amendments to the specification and claims herein are made only to accurately identify the appropriate sequences.

CONCLUSION

In view of the amendments, remarks and enclosures herein, it is respectfully submitted that the application now complies with all requirements set forth in the Notice. Accordingly, reconsideration and withdrawal of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply") is respectfully requested.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants



Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

Enclosures: Paper and Diskette copies of Sequence Listing
Copy of Notice to Response To Notice To Comply
Return receipt postcard

“VERSION WITH MARKINGS TO SHOW CHANGES MADE”

Page 8, line 11:

In one embodiment of the present invention the target cell is of a type which may be lysed as a result of an immunological response thereagainst. Advantageously, the target cell is a tumour cell or any diseased or foreign cell the presence of which is undesired in a patient, such as a cancer cell, leukaemia cell, a cell infected with the HIV virus or with any other microbe or virus, a cell responsible for detrimental activity in auto-immune disease, and so on. In order to accelerate the triggering of an immunological response against said target cell in a patient, said HLA class I molecule or fragment thereof will preferably be capable of producing a powerful immune response from the cellular immune system of the patient. Accordingly, said HLA class I molecule or fragment thereof may bind a viral or microbial peptide, preferably a viral or microbial peptide to which the patient is likely to have had previous exposure. In particular, said HLA class I molecule or fragment thereof may bind an influenza virus peptide, a measles virus peptide, an Epstein-Barr virus peptide, in particular an Epstein-Barr virus peptide comprising the RAKFFQLL (SEQ ID NO: 1) epitope of the lytic protein BZLFI, a Cytomegalovirus peptide, or a tetanus toxoid peptide. Alternatively, said HLA class I molecule or fragment thereof may bind any peptide which already has a strong cytotoxic T cell response or which is capable of inducing a powerful immune response. The allotype of said HLA class I molecule or fragment thereof may additionally be different from the allotype of the HLA class I molecules of the patient, so that an alloreactive response may additionally be triggered against said target cell.

Page 24, line 3:

T cells :

Human cytotoxic T cell clones 010 (specific for HLA-A2/gag 77-85 = SLYNTVATL (SEQ ID NO: 2) (Parker et al, *J Immunol.* 149, 1992, 3580-3587)) and IF9 (specific for HLA-A2/melan-A 26-35 = EAAGIGILTV (SEQ ID NO: 3) (Romero et al, *J. Immunol.* 159, 1997, 2366) were maintained in media supplemented with 5% human serum and IL-2 100 IU/ml.

Claim 13:

13. (Amended) A complex as claimed in claim 11 appended to claim 10, or claim 12, wherein said recognition peptide comprises a viral or microbial peptide, such as an influenza virus peptide, a measles virus peptide, an Epstein-Barr virus peptide, in particular an Epstein-Barr virus peptide comprising the RAKFFQLL (SEQ ID NO: 1) epitope of the lytic protein BZLF1, a Cytomegalovirus peptide, or a tetanus toxoid peptide.